https://european-biotechnology.net/wp-content/uploads/2025/11/AdobeStock_567963308-1030x579-1.jpeg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-27 11:55:512025-11-27 11:55:51Ventuno Biotech Secures €3m to Power Next-Gen Cancer Immunotherapies
https://european-biotechnology.net/wp-content/uploads/2025/11/Alzheimers-circadian-clock_759438370_9dNJSIceLEu9DJBjD9NMlsu6kb8qYerf-e1763879851169.jpg640958Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-21 17:31:592025-11-21 17:31:59Melatonin: a promising new approach in Alzheimer’s treatment
https://european-biotechnology.net/wp-content/uploads/2025/11/roche_2023-e1763538634371.jpg392699Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-19 07:51:262025-11-19 07:51:26Giredestrant demonstrates efficacy in early-stage breast cancer
https://european-biotechnology.net/wp-content/uploads/2025/11/30MioSerieA_Koskoppe-e1763454296760.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-18 08:25:052025-11-18 08:25:05Avanzanite secures €32m Series A funding
https://european-biotechnology.net/wp-content/uploads/2025/11/bayer-co-lab-eingang-logosIMG_9795.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-17 18:25:502025-11-17 18:25:50Millions Flow Into Captain T Cell as Berlin’s Cell Therapy Scene Defies the Gloom
https://european-biotechnology.net/wp-content/uploads/2025/11/Antoine-headshot-scaled-e1763109509367-1030x580-1.jpg5801030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-17 00:01:382025-11-17 00:01:38Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
